Author

Xueying Yuan

Baylor College of MedicineORCID 0000-0001-6242-7630Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:mouse· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alex J. SmithiD· 3 shared Diego A. PedrozaiD· 3 shared Fengshuo LiuiD· 3 shared Jeffrey M. RoseniD· 3 shared Na ZhaoiD· 3 shared Sebastian J. CalderoniD· 3 shared Charles M. PerouiD· 2 shared Hilda L. ChaniD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Alex J. SmithORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyCancer Immunology ResearchPeer-reviewedAug 17, 2026

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer

Alex J. Smith, Zachary Schrank, Nan Guan…·Jeffrey M. Rosen

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

DOI 10.1158/2326-6066.cir-26-0278

mousescRNA-seq

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedJan 3, 2026

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers

Diego A. Pedroza, Xueying Yuan, Fengshuo Liu…·Jeffrey M. Rosen

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

6 citationstop 1%

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJCI InsightPeer-reviewedSep 17, 2024

CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC

Xueying Yuan, Xiaoxin Hao, Hilda L. Chan…·Jeffrey M. Rosen

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.

15 citations

mouseexperimental assay

𝕏 PostBluesky